Nat Commun July 2023 PMID 37491373

Safety and anti-tumour activity of the IgE antibody MOv18 in patients with advanced solid tumours expressing folate receptor-alpha: a phase I trial.

James Spicer, Bristi Basu, Ana Montes, Udai Banerji, Rebecca Kristeleit, Rowan Miller, Gareth J Veal, Christopher J Corrigan, Stephen J Till, Mariangela Figini, Silvana Canevari, Claire Barton, Paul Jones, Sarah Mellor, Simon Carroll

Download social card

Mentions

Peak: 2 in Dec 2023

across 5 sources since Jul 2023

Extended reach

6,110

potential audience

Total likes

Video views

Mentions per month

Jul 2023 – Feb 2024

Where it's discussed

News29 articles
X / Twitter4 posts
Facebook2 posts
Blogs2 articles
YouTube1 videos

AI synopsis

What people are saying

Discussions show a balanced view, with some posts emphasizing the safety profile and potential anti-tumor activity, like mentions of tolerability and responses in specific cases, while others note the support from research institutions, indicating both scientific interest and cautious optimism about the trial's broader implications.

AgreementModerate agreement

Most discussions acknowledge the positive findings regarding the safety and potential efficacy of MOv18 IgE, with some expressing cautious optimism about its therapeutic promise.

InterestModerate interest

The social discussions show moderate interest, with participants engaging enough to mention supportive organizations and study details, indicating a general curiosity about the research.

EngagementModerate engagement

Many posts reference study specifics, such as dose escalation and side effects, reflecting a fair level of engagement and understanding of the trial's significance.

ImpactModerate impact

There is a consensus that this research could impact future cancer treatments, as several sources highlight the novel approach and its promising outcomes, though it remains preliminary.

Abstract in brief

A Phase I trial tested the safety and tolerability of MOv18 IgE, a new type of chimeric IgE antibody, in cancer patients whose tumors express folate receptor-alpha, with a focus on minimizing allergic reactions.
The study involved dose escalation from 70 μg to 12 mg, using skin prick and basophil activation tests to identify low-risk patients; the main side effect noted was temporary hives, with one case of anaphylaxis linked to pre-existing reactive basophils.
Results indicate that MOv18 IgE therapy is tolerable and shows potential anti-tumor activity, evidenced by a positive response in a patient with ovarian cancer, suggesting that IgE-based

Read the full abstract

All mentions

Evaluation of MOv18 IgE Antibody Safety and Anti-Tumor Effects in Cancer Patients

A phase I trial assessed the safety and tolerability of MOv18 IgE, a chimeric antibody targeting folate receptor-alpha in advanced solid tumor patients. The study found MOv18 IgE to be tolerable, with some side effects…

STEM RTCL TV · Oct 21, 2023 38 views

G Perdomo Gutiérrez

@gperdomog · X

Safety and anti-tumour activity of the IgE antibody MOv18 in patients with advanced solid tumours expressing folate receptor-alpha: a phase I trial -#20cyna https://t.co/iYaFEv8Nd2

Feb 3, 2024 · 835 followers View post →

Dataemia

@Dataemia · X

(Safety and anti-tumour activity of the IgE antibody MOv18 in patients with advanced solid tumours expressing folate receptor-alpha: a phase I trial) - https://t.co/lq3ehyDgPz -

Dec 2, 2023 · 968 followers View post →

UCL Discovery

@ucl_discovery · X

Open Access UCL Research: Safety and anti-tumour activity of the IgE antibody MOv18 in patients with advanced solid tumours expressing folate receptor-alpha: a phase I trial https://t.co/siMB7vrYjs

Dec 1, 2023 · 2,526 followers View post →

Stigmabase | NORTH

@StigmabaseN · X

Jul 26, 2023 · 1,744 followers View post →